Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. (January 2010)

• Record Type: Journal Article
• Authors: Henning, Robert J; Aufman, Jeffrey; Shariff, Masood; Sawmiller, Darrell; DeLostia, Vincent; Sanberg, Paul; Morgan, Michael
• Is Part Of: Regenerative medicine. Volume 5:Number 1(2010)
• Page Start: 45
• Page End: 54
• Publication Date: 2010-01
• Subjects: cardiomyopathy -- left ventricular ejection fraction -- umbilical cord blood stem cells -- ventricular fibrosis; Cellular therapy -- Periodicals; Stem cells -- Transplantation -- Periodicals; Degeneration (Pathology) -- Treatment -- Periodicals; Regeneration (Biology) -- Periodicals; 611.018
• DOI: 10.2217/rme.09.71
• Languages: English
• ISSNs: 1746-0751

Abstract

Aims: We investigated whether human umbilical cord blood mononuclear cells (HUCBC) can limit progressive cardiomyopathy in TO2 hamsters.Materials & methods: A total of 22 TO2 1-month-old hamsters were treated with intramyocardial HUCBC, 4 ×× 10 6 in Isolyte ®®, and 23 TO2 1-month-old hamsters were treated with intramyocardial Isolyte. A total of 16 1-month-old F1B hamsters served as controls and received intramyocardial Isolyte. Echocardiograms were performed on all hamsters prior to and monthly after treatment for 6 months. Heart tissues were then stained with hematoxylin and eosin, Masson''s Trichrome and human leukocyte antibody.Results: In F1B hamsters, left ventricular fractional shortening (FS) and ejection fractions (EF) did not significantly decrease over 6 months. By contrast, in Isolyte-treated TO2 hamsters, FS decreased from 56.2 ±± 1.0% to 19.7 ±± 3.2% and EF decreased from 89.5 ±± 1.4% to 44.9 ±± 5.9% at 6 months (both p < 0.0001). The FS and EF in HUCBC-treated TO2 hamsters also progressively decreased over 6 months but the changes were more gradual, especially during the first month after HUCBC treatment when FS was 52.0 ±± 1.5% and EF was 89.5 ±± 1.4%, which was not significantly different from the FS and EF in the F1B hamsters. Moreover, in the HUCBC-treated hamsters, the FS and EF were 20––30% greater than FS and EF in Isolyte TO2 hamsters at 3 and 5 months (p < 0.01). In Isolyte-treated TO2 hamsters at 6––7 months, fibrosis involved 30.0 ±± 5.0% of left ventricle and 35.0 ±± 5.0% of septum. By contrast, in HUCBC-treated hamsters, fibrosis involved only 6.5 ±± 2.3% of the left ventricle and 6.3 ±± 1.8% of septum (p < 0.05). The average number of blood vessels per myocardial microscopic field in HUCBC-treated hearts was 53.5 ±± 0.8 versus 46.2 ±± 3.0 in Isolyte-treated TO2 hearts (p < 0.05).Conclusion: HUCBC, when given as a single intramyocardial injection, can limit fibrosis and increase heart function over the short term in TO2 hamsters with cardiomyopathy.